Physician profile
David J Mann
NPI 1912223322
$1,429.46
in general payments reported to CMS, 2019-2025
26 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $178 · 2021: $105 · 2022: $83.58 · 2023: $147 · 2024: $30.17 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.88 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $169.26 | 2019-2024 | Aklief |
| Sun Pharmaceutical Industries INC. | $160.43 | 2019-2025 | |
| Amgen INC. | $147.62 | 2022-2024 | Otezla |
| Abbvie INC. | $124.53 | 2019-2020 | |
| Janssen Biotech, INC. | $119.39 | 2025 | Tremfya |
| Mayne Pharma Commercial LLC | $99.62 | 2019 | |
| Pfizer INC. | $71.90 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $62.96 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $59.58 | 2019 | |
| Leo Pharma INC. | $55.43 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.81 | 2019 | |
| Genzyme Corporation | $38.69 | 2019-2025 | |
| Dermira, INC. | $28.49 | 2019 | |
| Biofrontera INC. | $26.03 | 2019 | |
| Epi Health, LLC | $22.74 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $22.42 | 2023 | Puraply |
| Organon LLC | $22.42 | 2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $21.91 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $19.87 | 2025 | Sotyktu |
| Almirall LLC | $19.27 | 2019 | |
| Mission Pharmacal Company | $18.44 | 2019 | |
| Arcutis Biotherapeutics, INC. | $17.53 | 2023 | |
| Cipher Pharmaceuticals US LLC | $16.82 | 2025 | Spinosad, Natroba |
| Lilly USA, LLC | $14.46 | 2023 | Taltz |
| Glenmark Therapeutics INC. | $12.00 | 2019 | |
| Aclaris Therapeutics, INC. | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.